Monoclonal antibodies have great potential to be used effectively to protect against and treat infectious diseases. Their development into new drugs is more necessary than ever at a time when
Current developments in infection research challenge the scientific community: Many problems can only be solved if expertise from different disciplines comes together. To meet this challenge, the DZIF
EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective
According to the World Health Organisation (WHO), approximately 1.5 million people die each year from tuberculosis (TB), a disease of the lungs caused by Mycobacterium tuberculosis. People with a
The COVID-19 pandemic has dramatically demonstrated that the development of effective agents against viral pathogens is of great importance for global health. Although effective vaccines are available
